Skip to Content

BioAge Labs, Inc.

Securities Class Action

  • Date:
  • 3/10/2025
  • Company Name:
  • BioAge Labs, Inc.
  • Stock Symbol:
  • BIOA
  • Status:
  • Filed
  • Filing Date:
  • 1/7/2025
  • Court:
  • U.S. District Court: Northern California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioAge securities pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024 (the “Class Period”). Investors have until March 10, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.
 
Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
 
If you purchased or otherwise acquired BioAge shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in BioAge Labs. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: